XARELTO®: Dosing for venous thromboembolism (VTE) prophylaxis in acutely ill medical patients◇
XARELTO®: Once-daily oral dose for vte risk reduction in acutely ill medical patients both inpatient and outpatient
Once daily, in hospital and after hospital discharge, for a total recommended duration of 31 to 39 days with or without food in patients with CrCl ≥15 mL/min
Renal Dose Considerations*†
- Avoid using XARELTO® in patients with CrCl <15 mL/min
◇For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.
*Calculate CrCl based on actual weight.
†Patients with CrCl <30 mL/min were not studied, but administration of XARELTO® is expected to result in serum concentrations of rivaroxaban similar to those in patients with moderate renal impairment (CrCl 30 mL/min to <50 mL/min).
‡The decision regarding initiation setting should be based on the prescriber's clinical judgment.
CrCl = creatinine clearance; VTE= venous thromboembolism.